Indications and uses
• temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold • temporarily reduces fever
• temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold • temporarily reduces fever
• do not take more than directed • the smallest effective dose should be used • drink a full glass of water with each dose Adults and children 12 years and older: • take 1 tablet every 8 to 12 hours while symptoms last • for the first dose you may take 2 tablets within the first hour • do not exceed 2 tablets in any 8- to 12-hour period • do not exceed 3 tablets in a 24-hour period Children under 12 years: • ask a...
• each tablet contains: sodium 22 mg • store at 20-25°C (68-77°F). Avoid high humidity and excessive heat above 40°C (104°F).
Naproxen sodium 220 mg
(naproxen 200 mg) (NSAID)*
*nonsteroidal anti-inflammatory drug
Pain reliever/fever reducer
Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed.
ask a health professional before use. It is especially important not to use naproxen sodium at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Adults and children 12 years and older:
Children under 12 years:
FD&C blue no. 2 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, talc, titanium dioxide
1-855-423-2630
| Class | Version | Type | Effective |
|---|---|---|---|
| NAPROXEN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20191108 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fef6ad89-235f-4274-ba49-a8e53642473e | Product name | 2 | 20250225 |
| 87fed3e6-8fba-48ef-96b0-3a7fb54b96ff | Product name | 3 | 20230306 |
| b5fdaaec-7251-4da6-9cb2-4e9e76939ec8 | Product name | 1 | 20200623 |
| e76dbbc1-775d-722c-08ff-ed45e8a80def | Product name | 3 | 20181002 |
| 6f4f4521-fd56-1ae6-888b-3b021bd75c7c | Product name | 1 | 20140508 |
| ce67e27d-1d21-5465-4409-b0662dd99d4d | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 41163-707-71 | 2026-01-29 | C162847 | 48780-1 | 49896155-a104-586f-e063-e6dba90add90 | SuperValu Inc. Naproxen Sodium Tablets 220 mg Drug Facts |
| 41163-707-75 | 2026-01-29 | C162847 | 48780-1 | 49896155-a104-586f-e063-e6dba90add90 | SuperValu Inc. Naproxen Sodium Tablets 220 mg Drug Facts |
| 41163-707-78 | 2026-01-29 | C162847 | 48780-1 | 49896155-a104-586f-e063-e6dba90add90 | SuperValu Inc. Naproxen Sodium Tablets 220 mg Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 41163-707-71 | equaline naproxen sodium | 50 in 1 BOTTLE | TABLET, FILM COATED | 50 | 8 | |
| 41163-707-71 | equaline naproxen sodium | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 8 | |
| 41163-707-75 | equaline naproxen sodium | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 8 | |
| 41163-707-75 | equaline naproxen sodium | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 8 | |
| 41163-707-78 | equaline naproxen sodium | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 8 | |
| 41163-707-78 | equaline naproxen sodium | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 8 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 41163-707-71 | EA - Each | 41163-707 | 65463526-d541-40a6-8a05-736a79c911f9 | 1 | 2017-03-06 |
| 41163-707-78 | EA - Each | 41163-707 | b80c699e-2ed6-44cc-99b4-f733e8deb7e1 | 1 | 2016-10-06 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| NAPROXEN SODIUM | ACTIVE INGREDIENT | 9TN87S3A3C | 1 | |
| NAPROXEN | ACTIVE MOIETY | 57Y76R9ATQ | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| POLYETHYLENE GLYCOLS | INACTIVE INGREDIENT | 3WJQ0SDW1A | 1 | |
| POVIDONES | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 41163-707 | 41163-707-71, 41163-707-78, 41163-707-75 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NAPROXEN SODIUM | 9TN87S3A3C | ACTIB |
| FD&C BLUE NO. 2 ALUMINUM LAKE | 4AQJ3LG584 | IACT |
| HYPROMELLOSE, UNSPECIFIED | 3NXW29V3WO | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IACT |
| POLYETHYLENE GLYCOL, UNSPECIFIED | 3WJQ0SDW1A | IACT |
| POVIDONE, UNSPECIFIED | FZ989GH94E | IACT |
| TALC | 7SEV7J4R1U | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED / ORAL | 91 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED / ORAL | 91 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED / ORAL | 91 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED / ORAL | 91 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074661-001 | NAPROXEN SODIUM | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A074661-001 | NAPROXEN SODIUM | EQ 200MG BASE | TABLET / ORAL | 1997-01-13 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A074661-001 | NAPROXEN SODIUM | EQ 200MG BASE | TABLET / ORAL | 1997-01-13 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A074661-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1997-01-13 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| equaline naproxen sodium | NAPROXEN SODIUM | United Natural Foods, Inc. dba UNFI | 89c02e55-fa08-4001-96fc-8a01e7e74d5a | 2026-05-06 | Warnings | 41163-707-78 41163-707-71 41163-707-75 41163-707 41163070775 41163070771 41163070778 726f2b53-4a2f-42db-8e7c-75da538df3fd 89c02e55-fa08-4001-96fc-8a01e7e74d5a |
Adverse event summaries are temporarily unavailable. Other product information remains available.